Regular Cannabis Users Required 220% More Propofol in Oral Surgery Study

Daily Users Required 220% Higher Propofol Doses

The JOMS cohort study tracked anesthesia requirements across 300 third-molar extraction cases and found daily cannabis users needed an average 220% more propofol to reach target sedation depth. Researchers at the University of Colorado School of Dental Medicine measured propofol bolus totals, midazolam adjunct use, and recovery times across three patient groups: daily users (≥5 days/week), occasional users (<5 days/week), and non-users.

Daily users averaged 340mg total propofol. Non-users? Just 110mg. Occasional users fell between at 180mg. All cohorts reached equivalent Ramsay Sedation Scale scores, but daily users required 18 minutes longer chair time to achieve initial sedation. No adverse events were recorded in any group.

The study controlled for body mass index, age, and opioid co-use. The tolerance effect persisted even among patients who reported abstaining for 48 hours prior to surgery, suggesting receptor-level adaptation rather than acute cannabinoid interference.

Mechanism: CB1 Receptor Cross-Talk With GABA Systems

The anesthesia resistance likely stems from CB1 receptor downregulation in chronic users, which indirectly modulates GABAergic signaling pathways that propofol and benzodiazepines depend on. Propofol works by enhancing GABA-A receptor activity. Chronic THC exposure downregulates CB1 receptors in the prefrontal cortex and hippocampus—regions dense with GABAergic interneurons.

When CB1 tone drops, compensatory upregulation of glutamatergic signaling occurs. This raises the threshold for GABA-mediated sedation. The result: a patient who metabolizes propofol normally but requires higher plasma concentrations to achieve the same clinical effect.

This isn't metabolic tolerance (faster drug clearance). It's pharmacodynamic tolerance—the receptor landscape has shifted. Daily benzodiazepine users show similar propofol resistance, but the magnitude in this cannabis cohort exceeded prior benzo studies by roughly 40%.

Implications for Perioperative Protocols and Patient Disclosure

The findings argue for routine preoperative cannabis-use screening and individualized anesthesia titration protocols, especially in outpatient oral surgery where underdosing risks patient movement and overdosing risks respiratory depression. Most oral surgery consent forms ask about alcohol and tobacco but skip cannabis. That gap is now a patient-safety issue.

The Colorado team recommends starting propofol infusions at 1.5× standard induction doses for self-reported daily users, with real-time BIS (bispectral index) monitoring to avoid overshoot. Recovery times in the study were equivalent across groups once target sedation was reached, meaning higher doses didn't prolong discharge—they just required more drug to get there.

For anesthesia providers, the operational headache is inventory and documentation. A case that normally consumes one 200mg propofol vial may now require two. That's a cost and controlled-substance tracking burden. For full background on perioperative cannabis considerations, see the CannIntel topic hub on cannabis and anesthesia interactions.

One variable remains unmodeled: does consumption method matter? The study didn't differentiate between smoked flower, vaporized concentrates, and edibles. If the tolerance effect is dose-dependent, high-potency concentrate users might need even higher anesthesia loads. We'll be watching for follow-up studies that stratify by THC plasma levels rather than self-reported frequency.